로딩 중...
52주 최고가 대비 59.6% 위치
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
SEC 13F 공시 기준 · 2025-Q4
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $1.56B | $1.71B | $2.11B | $2.25B |
| 영업이익 | - | $-90.7M | $-48.4M | $-103.4M | $-18.9M |
| 당기순이익 | - | $-13.3M | $-33.3M | $-825.5M | $-1.18B |
| 잉여현금흐름 (FCF) | - | $-161.3M | $12.8M | $-67.2M | $19.9M |
| 수익성 비율 | |||||
| 영업이익률 | - | -5.8% | -2.8% | -4.9% | -0.8% |
| 순이익률 | - | -0.9% | -1.9% | -39.2% | -52.7% |
| ROE (자기자본이익률) | - | -0.4% | -1.0% | -32.2% | -79.5% |
| ROA (자산이익률) | - | -0.3% | -0.7% | -17.5% | -30.9% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 9.2% | 23.5% | 6.7% |
| EPS 성장률 (YoY) | - | - | -144.0% | -2347.5% | -39.0% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | - |
| PBR (주가순자산배수) | - | 1.1x | 1.0x | 1.1x | 0.9x |
| PSR (주가매출배수) | - | 2.3x | 2.0x | 1.3x | 0.6x |
| FCF Yield | - | -4.5% | 0.4% | -2.5% | 1.6% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.10 | 0.16 | 0.55 | 0.93 |
| 유동비율 | - | 1.41 | 2.43 | 2.17 | 2.02 |
MOLINA HEALTHCARE INC
$179.86
$9.4B